Talon Pharmaceuticals
A multiphore drug design platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | - | ||
| Total Funding | 000k | ||
Related Content
Talon Pharmaceuticals, founded in 2012 by David Vaughan and Shawn Maddaford, is a privately held drug discovery company headquartered in Mississauga, Canada. The firm specializes in the development of small-molecule therapeutics aimed at treating central nervous system disorders and challenging bacterial infections. The company's strategic focus is on creating multi-action drugs that target more than one mechanism of action to address complex diseases.
Shawn Maddaford, serving as President and Chief Scientific Officer, brings over 25 years of drug discovery and development experience to the company, having co-founded two other chemistry-focused R&D companies. His expertise in neurological disorders, medicinal chemistry, and patent strategy is central to the company's scientific direction. This background directly informs Talon's core mission of designing purpose-built medicines for neurodegenerative diseases.
Talon's primary efforts are geared towards improving the quality of life for patients with Parkinson's disease by developing treatments to reduce symptoms like levodopa-induced dyskinesia and psychosis. The company utilizes a proprietary multiphore discovery platform, which designs a single drug to interact with multiple disease targets. Its pipeline is currently in the preclinical and discovery stages; the lead candidate, TPS-100, is being developed for the treatment of motor coordination and neurodegeneration in ARSACS (Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay). Additional research programs are exploring small molecules for ALS and multi-drug resistant bacteria. The company has received grant funding and support from accelerator programs to advance its research.
Keywords: drug discovery, neurodegenerative disorders, small-molecule therapeutics, Parkinson's disease, central nervous system disorders, biotechnology, bacterial infections, multi-action drugs, ARSACS, preclinical research, medicinal chemistry, Shawn Maddaford, David Vaughan, levodopa-induced dyskinesia, multiphore discovery platform, motor coordination, ALS treatment, antibiotic resistance, pharmaceutical development, life sciences
